Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
НЦПЗ РАМН, Москва
Список исп. литературыСкрыть список 1. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MTI and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 553–61. 2. Goodwin GM, Rouillon F, Emsley R. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months [abstract]. In: 21st European College of Neuropsychopharmacology Congress; 30 Aug-3 Sept 2008; Bareelone. Spain. Eur Neuropsychopharma-col 2008; 18: S338–9. 3. Kennedy SH. Agomelatine. Efficacy at Each Phase of Antidepressant Treatment. CNS Drugs 2009; 23 (Suppl. 2): 41–7. 4. Kennedy SH, Rizvi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329–33. 5. Lader M. Pharmacotherapy of mood disorders and treat-ment discontinuation. Drugs 2007; 67: 1657–63. 6. Lemoine P, Guilleminault C, Alvarez E. Improvement in sub-jective sleep in major depressive disorder with a novel anti-depressant, agomelatine: randomized, double-blind compar-ison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 7. LЩo H, Hale A, D\'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 8. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydro-xytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 9. Montgomery SA. Why do we need new and better antidepressants? Int Clin Psychopharmacol 2006; 21 (Suppl. 1): Sl–10. 10. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–91. 11. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80. 12. Quera Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG. and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691–6. 13. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry 2003; 64 (Suppl. 18): 3–7.